Interleukin-2 microencapsulated - Carlina Technologies

Drug Profile

Interleukin-2 microencapsulated - Carlina Technologies

Alternative Names: PEPTIDOTS-IL2

Latest Information Update: 07 Nov 2014

Price : $50

At a glance

  • Originator Carlina Technologies
  • Class Adjuvants; Antineoplastics; Interleukins; Lymphokines
  • Mechanism of Action Immunostimulants; Interleukin-2 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Research Renal cell carcinoma; Skin cancer

Most Recent Events

  • 06 Nov 2014 Early research in Renal cell carcinoma in France (SC)
  • 06 Nov 2014 Early research in Skin cancer in France (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top